



(11)

EP 2 270 052 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
G01N 33/53 ^(2006.01) **A61P 19/08** ^(2006.01)

(48) Corrigendum issued on:
02.05.2018 Bulletin 2018/18

(45) Date of publication and mention
of the grant of the patent:
28.03.2018 Bulletin 2018/13

(21) Application number: **10181323.6**

(22) Date of filing: **25.06.2002**

(54) **Antibodies to OPGL**
Antikörper gegen OPGL
Anticorps anti-OPGL

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **26.06.2001 US 301172 P**

(43) Date of publication of application:
05.01.2011 Bulletin 2011/01

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
**09156995.4 / 2 087 908
02749660.3 / 1 409 016**

(73) Proprietors:
• **Amgen Inc.**
Thousand Oaks, CA 91320 (US)
• **Amgen Fremont Inc.**
Thousand Oaks, CA 91320 (US)

(72) Inventors:
• **Boyle, William**
Malibu, CA 90265 (US)
• **Martin, Francis**
Newbury Park, CA 91320 (US)
• **Corvalan, Jose**
Foster City, CA 94404 (US)

• **Davis, Geoffrey**
Burlingame, CA 94010 (US)

(74) Representative: **Dörries, Hans Ulrich**
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München (DE)

(56) References cited:
WO-A-02/053596 WO-A1-98/46751

• **TSUKII K ET AL: "Osteoclast differentiation factor
mediates an essential signal for bone resorption
induced by 1 alpha,25-dihydroxyvitamin D3,
prostaglandin E2, or parathyroid hormone in the
microenvironment of bone", BIOCHEMICAL AND
BIOPHYSICAL RESEARCH COMMUNICATIONS,
ACADEMIC PRESS INC. ORLANDO, FL, US, vol.
246, no. 2, 19 May 1998 (1998-05-19), pages
337-341, XP002169940, ISSN: 0006-291X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 270 052 B8

- NAGAI M KYAKUMOTO S SATO N: "Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 269, 16 March 2000 (2000-03-16), pages 532-536, XP002956545, ISSN: 0006-291X
- MARTIN WELSCHOF ET AL: "The Antigen Binding Domain of Non-idiotypic Human Anti-F(ab')₂ Autoantibodies: Study of their Interaction with IgG Hinge Region Epitopes", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 60, no. 4, 1 April 1999 (1999-04-01), pages 282-290, XP008131561, ISSN: 0198-8859
- PAVLINKOVA G ET AL: "Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAbs CC49 in colon carcinomaxenografts.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE SEP 1999 LNKD-PUBMED:10492377, vol. 40, no. 9, September 1999 (1999-09), pages 1536-1546, XP002616970, ISSN: 0161-5505
- FOR THE ATTRACT STUDY GROUP MAINI R ET AL: "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 354, no. 9194, 4 December 1999 (1999-12-04), pages 1932-1939, XP004827470, ISSN: 0140-6736, DOI: DOI:10.1016/S0140-6736(99)05246-0
- 3, 24: In: Alberts et al: "Molecular Biology Of The Cell - fourth edition", 2002, Garland Science, New York page 162, 1380, 1381,
- KATO Y ET AL: "Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 37, no. 7, 1 October 2010 (2010-10-01), pages 785-794, XP027325962, ISSN: 0969-8051 [retrieved on 2010-09-23]
- ABRAHAM R ET AL: "Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays", JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 9, no. 5-6, 1 September 1996 (1996-09-01), pages 456-461, XP002381122, ISSN: 0952-3499, DOI: 10.1002/(SICI)1099-1352(199634/12)9:5/6<456::AID-JMR282>3.0.CO;2-8
- LARVOR M P ET AL: "Measurement of the dissociation rate constant of antigen/antibody complexes in solution by enzyme-linked immunosorbent assay.", JOURNAL OF IMMUNOLOGICAL METHODS 15 APR 1994, vol. 170, no. 2, 15 April 1994 (1994-04-15), pages 167-175, ISSN: 0022-1759
- ZHUANG G ET AL: "Measurement of association rate constant of antibody-antigen interaction in solution based on enzyme-linked immunosorbent assay.", JOURNAL OF BIOSCIENCE AND BIOENGINEERING 2001, vol. 92, no. 4, 2001, pages 330-336, ISSN: 1389-1723
- HARDY F ET AL: "Measurement of antibody/antigen association rate constants in solution by a method based on the enzyme-linked immunosorbent assay.", JOURNAL OF IMMUNOLOGICAL METHODS 15 JAN 1997, vol. 200, no. 1-2, 15 January 1997 (1997-01-15), pages 155-159, ISSN: 0022-1759